NextCure Inc. has announced a one-for-twelve reverse stock split of its common stock, effective July 14, 2025. The stockholders approved an amendment enabling a reverse stock split at a ratio between one-to-five and one-to-fifteen, with the board of directors deciding on the final ratio. No fractional shares will be issued; instead, stockholders will receive cash for any fractional shares based on the closing price before the split. The common stock will trade on a split-adjusted basis on the Nasdaq Global Select Market under the ticker symbol "NXTC".
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.